Lung cancer - 4: Chemotherapy for non-small cell lung cancer: the end of the beginning

被引：10

作者：

Cullen, M ^{[1
]}

机构：

[1] Queen Elizabeth Hosp, Ctr Canc, Birmingham B15 2TH, W Midlands, England

来源：

THORAX | 2003年 / 58卷 / 04期

关键词：

D O I：

10.1136/thorax.58.4.352

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The development of chemotherapy for NSCLC over the last 20 years is reviewed, particularly with regard to its palliative effects. New "fourth generation" agents designed to inhibit specific biological pathways thought to be crucial to tumour growth give cause for optimism in the future treatment of NSCLC.

引用

页码：352 / 356

页数：5

共 39 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].

Anderson, H. ;

Hopwood, P. ;

Stephens, R. J. ;

Thatcher, N. ;

Cottier, B. ;

Nicholson, M. ;

Milroy, R. ;

Maughan, T. S. ;

Falk, S. J. ;

Bond, M. G. ;

Burt, P. A. ;

Connolly, C. K. ;

McIllmurray, M. B. ;

Carmichael, J. .

BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453

[3]

Archer V R, 1999, Oncologist, V4, P470

[4] The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer [J].

Billingham, LJ ;

Cullen, MH .

ANNALS OF ONCOLOGY, 2001, 12 (12) :1671-1675

[5]

Bonomi P, 2000, CLIN CANCER RES, V6, p4544S

[6] Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].

Bonomi, P ;

Kim, KM ;

Fairclough, D ;

Cella, D ;

Kugler, J ;

Rowinsky, E ;

Jiroutek, M ;

Johnson, D .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631

[7] Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer [J].

Bredin, M ;

Corner, J ;

Krishnasamy, M ;

Plant, H ;

Bailey, C ;

A'Hern, R .

BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7188) :901-904

[8] Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:: A randomized phase III study of the Italian lung cancer project [J].

Crinò, L ;

Scagliotti, GV ;

Ricci, S ;

De Marinis, F ;

Rinaldi, M ;

Gridelli, C ;

Ceribelli, A ;

Bianco, R ;

Marangolo, M ;

Di Costanzo, F ;

Sassi, M ;

Barni, S ;

Ravaioli, A ;

Adamo, V ;

Portalone, L ;

Cruciani, G ;

Masotti, A ;

Ferrara, G ;

Gozzelino, F ;

Tonato, M .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3522-3530

[9] Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].

Cullen, MH ;

Billingham, LJ ;

Woodroffe, CM ;

Chetiyawardana, AD ;

Gower, NH ;

Joshi, R ;

Ferry, DR ;

Rudd, RM ;

Spiro, SG ;

Cook, JE ;

Trask, C ;

Bessell, E ;

Connolly, CK ;

Tobias, J ;

Souhami, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194

[10]

CULLEN MH, 2001, LANCET ONCOLOGY, V3, P173

← 1 2 3 4 →